President Trump announced a sweeping 100% tariff on all imported generic pharmaceutical drugs this Tuesday. The administration stated the measure’s goal is to revitalize domestic drug manufacturing within the United States. This tariff is expected to significantly increase the cost of generic medications for consumers. Implementation of the tariffs is scheduled for August 2028, allowing time for potential adjustments within the industry. Critics argue the tariffs will harm patients by limiting access to affordable medications and could disrupt the supply chain. The White House maintains the long-term benefits of a strengthened US pharmaceutical sector will outweigh these concerns. This policy represents a major shift in the administration’s trade approach to the pharmaceutical industry.